Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
Wolfgang Miesbach/LinkedIn
Aug 16, 2025, 14:54

Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X:

“՛CRISPR-Cas9 Clinical Safety: Off-Target Assessment Framework — A recently published review highlights the need for advanced strategies to address off-target effects, the most significant challenge in therapeutic genome editing.

CRISPR-Cas9 Overview
CRISPR-Cas9 uses programmable nucleases comprising Cas9 endonuclease and guide RNA (gRNA) to create targeted double-strand breaks with base-pair precision. Current therapeutic applications include treating β-hemoglobinopathies via BCL11A enhancer targeting, demonstrated by Casgevy—the first FDA-approved CRISPR therapy.

Off-Target Effects -Critical Safety Challenge
Off-target activity occurs when CRISPR-Cas9 cleaves unintended genomic loci, potentially:

  • Disrupting tumor suppressor genes or proto-oncogenes
  • Generating large structural variants (deletions, inversions, translocations)
  • Causing chromosomal instability and potential malignant transformation

Clinical reality: Over 100 active CRISPR clinical trials are underway, yet safety assessment protocols remain inconsistent.

Five-Tier Safety Assessment Framework
The authors propose a clear five-step safety evaluation:

1. Computational gRNA Design
In silico prediction tools identify potential off-target sites
High-fidelity Cas variants reduce off-target binding
2. Experimental Off-Target Nomination
Cell-free and cell-based assays provide genome-wide detection
Orthogonal validation using multiple methodologies
3. Structural Variant Detection
Long-read sequencing identifies large deletions and rearrangements
Digital PCR quantifies specific variants with high sensitivity
4. Functional Safety Assessment
In vitro transformation assays evaluate oncogenic potential
Single-cell sequencing links genotype to phenotype
5. Regulatory Compliance
GMP-grade manufacturing ensures consistent quality
FDA/EMA guidelines mandate comprehensive characterization

Personalized Safety Considerations
Population-specific variants can create or eliminate off-target sites. Solution: Variant-aware prediction tools incorporate individual genetic profiles to identify population-specific or patient-specific risks.

The Path Forward
Standardizing rigorous safety frameworks while maintaining innovation pace remains the key challenge. As CRISPR transitions from experimental tool to clinical standard, comprehensive off-target assessment becomes scientifically essential and ethically imperative for patient safety.
Congratulations to Nechama Kalter and co-authors.”

Read the full article here.

Title: Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges

Authors: Nechama Kalter, Carla Fuster-García, Alfredo Silva, Víctor Ronco-Díaz, Stefano Roncelli, Giandomenico Turchiano, Jan Gorodkin, Toni Cathomen, Karim Benabdellah, Ciaran Lee, Ayal Hendel

Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing

Stay updated on the latest scientific advances with Hemostasis Today.

Alfredo Silva Ayal Hendel BCL11A enhancer Carla Fuster-García Casgevy Ciaran Lee CRISPR Safety CRISPR therapy CRISPR-Cas9 FDA-approved Genome Editing Giandomenico Turchiano Health Hematology Hemostasis Today Jan Gorodkin Karim Benabdellah Medicine Nechama Kalter Stefano Roncelli Toni Cathomen Víctor Ronco-Díaz
NewsFeed